Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.
Journal: Cell reports. Medicine
Published: February 26, 2024
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Journal: Science translational medicine
Published: November 09, 2022
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.
Journal: Science translational medicine
Published: November 15, 2019
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Journal: Science translational medicine
Published: January 25, 2019
Showing 1-4 of 4
Last Updated: 09/26/2026